Siemsen A W, Dunea G, Mamdani B H, Guruprakash G
Nephron. 1978;22(4-6):386-90. doi: 10.1159/000181480.
16 patients with end-stage renal disease were treated with a fixed-bed, uncoated-charcoal hemoperfusion device, used either alone or in series with a hemodialyzer. 3 patients had one of their thrice weekly dialyses replaced by one 3 hour combined treatment for up to 6 months, and 3 patients had 150-min combined treatments thrice weekly for up to 5 months. The procedure was well tolerated. Transient hypotension occurred and interfered with fluid removal by ultrafiltration. Platelet counts were reduced, but there was no clinical bleeding. Pretreatment of the device with albumin provided no advantage over heparinized saline, and dextran caused a more severe reduction in the platelet count. The changes in platelets, white blood cells, and hematocrit were transient and noncumulative. Considerable amounts of creatinine and uric acid were removed. Regular charcoal hemoperfusion appears to be safe, and long-term studies of clinical efficacy are indicated.
16例终末期肾病患者接受了固定床、未包被活性炭血液灌流装置治疗，该装置可单独使用或与血液透析器串联使用。3例患者将每周3次的透析中的1次替换为1次3小时的联合治疗，持续6个月，3例患者每周进行3次150分钟的联合治疗，持续5个月。该治疗方法耐受性良好。出现了短暂性低血压，干扰了超滤脱水。血小板计数降低，但无临床出血。用白蛋白预处理该装置与肝素盐水相比并无优势，而右旋糖酐导致血小板计数下降更为严重。血小板、白细胞和血细胞比容的变化是短暂的且无累积效应。大量的肌酐和尿酸被清除。定期进行活性炭血液灌流似乎是安全的，有必要对临床疗效进行长期研究。
